Biotech company Promedior merges with Roche
Roche has successfully completed its purchase of Promedior, Inc. along with its entire portfolio of fibrotic disease therapeutics.
List view / Grid view
Roche has successfully completed its purchase of Promedior, Inc. along with its entire portfolio of fibrotic disease therapeutics.
2 September 2015 | By Victoria White
As well as granting exclusive rights to acquire Promedior, the agreement grants Bristol-Myers Squibb worldwide rights to Promedior's lead asset PRM-151.